Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients

Completed

Conditions studied: Breast Cancer

In brief

The goal of this clinical research study is to learn whether different ways of viewing echocardiogram pictures along with blood tests can help to see heart-related side effects of chemotherapy and trastuzumab earlier than the usual tests.

Key facts

Study ID

NCT00806507

Run by

M.D. Anderson Cancer Center

People needed

45

Starts

2008-11-01

Expected to finish

2011-08-01

Last updated by the study team

2012-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• HER-2 positive breast cancer
• Scheduled to receive Herceptin infusion therapy after exposure to anthracycline-based chemotherapy in one of the following manners: Adjuvant or neoadjuvant treatment with anthracycline-based chemotherapy preceded or followed by Herceptin infusion therapy, Herceptin monotherapy in patients with metastatic disease previously treated with anthracycline-based chemotherapy, Herceptin in combination with non-anthracycline chemotherapy in patients with metastatic disease previously treated with anthracycline-based chemotherapy
• Normal baseline left ventricular ejection fraction.

You may not qualify if…

• Pre-existing cardiomyopathy (Left Ventricular Ejection Fraction (LVEF) < 50%)
• Other contraindication to Herceptin therapy

Where it is running

• Partners Healthcare Systems — Boston, Massachusetts, United States
• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.